Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
11 July 2022 | Story Andre Damons | Photo Supplied
Prof Martie Smith and Prof Drik Opperman
Prof Martie Smit and Prof Dirk Opperman in the Department of Microbiology and Biochemistry filed a patent entitled “Process for the chemical modification of alkanes, fatty acids and fatty alcohols”.

Flavours and fragrances have a wide application in the food, feed, cosmetic, chemical and pharmaceutical sectors. Many flavour compounds are still produced via chemical synthesis or via extraction from plant or animal sources. However, there is increasing interest in their bio-production or the use of flavour compounds of (micro) biological origin. 

One reason for this shift is that chemical synthesis often uses environmentally unfriendly processes. Chemical synthesis usually also produces racemic mixtures with the second enantiomer, mirror image of the looked-for compound, often having undesirable organoleptic properties. Furthermore, the consumer has developed a “chemophobia”-attitude towards synthetic chemical compounds, especially when related to food and home-care products.  This applies even to nature-identical compounds – products that occur in nature but are produced via a non-natural chemical process. Products produced with the use of enzymes or microbes from “natural” substrates can be labelled “natural”. The flavour and fragrance industry thus pay higher prices for such products labelled as “natural”.  

The invention

A University of the Free State (UFS) team, led by Prof Martie Smit and Prof Dirk Opperman in the Department of Microbiology and Biochemistry are conducting exciting research in this area. They filed a patent entitled “Process for the chemical modification of alkanes, fatty acids and fatty alcohols”.  

The invention relates to a process for the enzymatic in-chain hydroxylation of C12 to C16 fatty acids, alcohols, and alkanes. Hydroxylation of C12 fatty acid and alcohol provides routes for the synthesis of “natural” δ-dodecalactone. The advantage of these routes is that they do not rely on massoia lactones. Massoia lactones are derived from the bark of Massoia trees which grow in Indonesia. Harvesting of the bark kills the trees.  

The cytochrome P450 enzymes (P450s) claimed in this patent are to the inventors’ knowledge the most regioselective enzymes described thus far that can be used for the synthesis of δ-dodecalactone from lauric acid or 1-dodecanol. The approach that the technology takes is to claim cytochrome P450 enzymes that share 70 % amino acid identity to a set of selected P450s for the regioselective hydroxylation of lauric acid and 1-dodecanol to synthesise δ-dodecalactone.

Still in early stage

The current state of development is early stage with the technology only demonstrated in the laboratory on a small scale (100-200 ml). Before the technology can be commercialised the team would need to further improve the regioselectivity and stability of the P450s and proof that the reactions can be scaled up in bioreactors. The technology will probably be delivered as an enzyme (amino acid sequence) with the desired properties. 

There are other research groups working on a synthetic biology approach for the de novo synthesis of δ-dodecalactone from glucose by genetically engineered microbes. It is still unclear how such a process will compare in terms of product yields, economics and environmental impact with the processes proposed by the UFS patent.

If the team had to partner with a commercial company, their first choice would be to work with an established flavour and fragrance company. Another possibility would be the small French flavour and fragrance company that Dr Alizé Pennec, the post-doc and co-inventor who initially discovered the unique P450 activity, is working for.

Please view the videos for more information on patents.

The Vice-Rector: Research and Internationalisation has released two new calls for applications for funding. Academic staff and researchers are encouraged to submit applications for these funds. At this stage we are not accepting projects from Research Fellows. 

The two funds are: 

1.  The Industrial Engagement Fund 
2.  The Intellectual Property Commercialisation Fund

Each fund has its own guidelines and application process. The guidelines are attached. The applications must be filled in on RIMS.

The RIMS application forms can be found through this link

For more information please click the documents below:



News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept